Literature DB >> 8506342

p53 gene mutations and protein accumulation in human ovarian cancer.

J Kupryjańczyk1, A D Thor, R Beauchamp, V Merritt, S M Edgerton, D A Bell, D W Yandell.   

Abstract

Mutations of the p53 gene on chromosome 17p are a common genetic change in the malignant progression of many cancers. We have analyzed 38 malignant tumors of ovarian or peritoneal müllerian type for evidence of p53 variations at either the DNA or protein levels. Genetic studies were based on single-strand conformation polymorphism analysis and DNA sequencing of exons 2 through 11 of the p53 gene; mutations were detected in 79% of the tumors. These data show a statistically significant association between mutations at C.G pairs and a history of estrogen therapy. Two of 20 patients whose normal tissue could be studied carried germ-line mutations of p53. Immunohistochemical analysis of the p53 protein was carried out using monoclonal antibody PAb1801. Ninety-six percent of the missense mutations were associated with abnormal accumulation of p53 protein, but nonsense mutations, a splicing mutation, and most deletions did not result in p53 protein accumulation. A statistically significant association between p53 protein accumulation in poorly differentiated stage III serous carcinomas and small primary tumor size at diagnosis was found, perhaps suggesting that p53 protein accumulation accelerates the metastatic spread from a primary tumor. Overall, our findings indicate that alterations of p53 play a major role in ovarian cancer, including predisposition to the disease in some patients, and suggest a possible mechanism for somatic mutations leading to this cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506342      PMCID: PMC46633          DOI: 10.1073/pnas.90.11.4961

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

Authors:  L Banks; G Matlashewski; L Crawford
Journal:  Eur J Biochem       Date:  1986-09-15

Review 2.  Tumor suppressor genes.

Authors:  C J Marshall
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

3.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

4.  Detection of DNA sequence polymorphisms by enzymatic amplification and direct genomic sequencing.

Authors:  D W Yandell; T P Dryja
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

5.  Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior.

Authors:  W R Hart; H J Norris
Journal:  Cancer       Date:  1973-05       Impact factor: 6.860

6.  Neoplastic transformation of rat 3Y1 cells by a transcriptionally activated human c-myc gene and stabilization of p53 cellular tumor antigen in the transformed cells.

Authors:  K Shiroki; K Segawa; Y Koita; M Shibuya
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

7.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

Review 8.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

9.  The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.

Authors:  T Takahashi; T Takahashi; H Suzuki; T Hida; Y Sekido; Y Ariyoshi; R Ueda
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

10.  Frequent p53 mutations in chemically induced murine fibrosarcoma.

Authors:  O Halevy; J Rodel; A Peled; M Oren
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

View more
  64 in total

Review 1.  Molecular genetics of ovarian cancer.

Authors:  A N Shelling; W Foulkes
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

2.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines.

Authors:  Sang Young Ryu; Kidong Kim; Woo Sik Lee; Hee Chung Kwon; Kee Ho Lee; Chang Min Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

4.  Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.

Authors:  Kathy Q Cai; Hong Wu; Andres J Klein-Szanto; Xiang-Xi Xu
Journal:  Gynecol Oncol       Date:  2009-04-16       Impact factor: 5.482

5.  Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.

Authors:  Hong-Yi Cai; Xiao-Hu Wang; Ying Tian; Li-Ying Gao; Li-Juan Zhang; Zhi-Yan Zhang
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

Review 6.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 7.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

8.  p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity.

Authors:  P Röhlke; K Milde-Langosch; C Weyland; U Pichlmeier; W Jonat; T Löning
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

9.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis.

Authors:  L Riethdorf; C Begemann; S Riethdorf; K Milde-Langosch; T Löning
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.